3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
PSA Level Greater Than Two
1
Hormone Sensitive Prostate Cancer
1
HER2 Negative Breast Cancer
1
Castrate Sensitive Prostate Cancer
1
Breast Neoplasms, Male
1
Interventions
Carboplatin
13
pembrolizumab
12
Specimen Handling
9
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Capecitabine
5
Biopsy
5
Nivolumab
4
Cyclophosphamide
4
sacituzumab govitecan
3
Gemcitabine
3
Fulvestrant
3
olaparib
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Taxes
2
Letrozole
2
Epirubicin
2
Docetaxel
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
veliparib
1
trastuzumab deruxtecan
1
toripalimab
1
sintilimab
1
pyrotinib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Goserelin
×
30 days
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled